Treatment of neonatal candidiasis with liposomal amphotericin B(L-AMP-LRC-1): phase II study.
Indian Pediatr
;
2003 Jun; 40(6): 545-50
Artículo
en Inglés
| IMSEAR
| ID: sea-7977
ABSTRACT
A liposomal amphotericin B preparation (L-AMP-LRC-1) has been developed and tested successfully in adults by us. This preparation was administered to 23 neonates with candidiasis in an open phase II study. All the 14 assessable patients responded completely to the L-AMP-LRC-1 therapy given at 1 mg/kg for 28 days. Compared to AmBisome, another liposomal formulation of amphotericin B, L-AMP-LRC-1 was effective at lower dose in neonatal candidiasis. Thus L-AMP-LRC-1 appears to be an effective and low cost drug for the treatment of candidiasis.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Femenino
/
Humanos
/
Masculino
/
Candidiasis
/
Recién Nacido
/
Anfotericina B
/
Resultado del Tratamiento
/
Lactante
/
Liposomas
/
Antifúngicos
Idioma:
Inglés
Revista:
Indian Pediatr
Año:
2003
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS